1.Levey AS, James MT. Acute Kidney Injury. Ann Intern Med 2017; 167(9): ITC66-ITC80.
2.Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379(9818): 815–822.
3.Kidney Disease Statistics for the United States. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease, 2018.
4.Shu S, Wang Y, Zheng M, et al. Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair. Cells 2019; 8(3).
5.Humphreys BD. Mechanisms of Renal Fibrosis. Annu Rev Physiol 2018; 80: 309–326.
6.Gewin LS. Renal fibrosis: Primacy of the proximal tubule. Matrix Biol 2018; 68–69: 248–262.
7.Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 2014; 124(6): 2299–2306.
8.Jager KJ, Fraser SDS. The ascending rank of chronic kidney disease in the global burden of disease study. Nephrol Dial Transplant 2017; 32(suppl_2): ii121-ii128.
9.Lovisa S, LeBleu VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 2015; 21(9): 998–1009.
10.Liu J, Zhong Y, Liu G, et al. Role of Stat3 Signaling in Control of EMT of Tubular Epithelial Cells During Renal Fibrosis. Cell Physiol Biochem 2017; 42(6): 2552–2558.
11.Grande MT, Sanchez-Laorden B, Lopez-Blau C, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med 2015; 21(9): 989–997.
12.Rockey DC, Bell PD, Hill JA. Fibrosis—a common pathway to organ injury and failure. N Engl J Med 2015; 372(12): 1138–1149.
13.Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007; 7(1): 39–47.
14.Xu H, Jiang H, Xie J. New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases. Front Mol Neurosci 2017; 10: 71.
15.Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010; 11(10): 682–696.
16.Marquard J, Otter S, Welters A, et al. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med 2015; 21(4): 363–372.
17.Rastaldi MP, Armelloni S, Berra S, et al. Glomerular podocytes contain neuron-like functional synaptic vesicles. FASEB J 2006; 20(7): 976–978.
18.Yang CC, Chien CT, Wu MH, et al. NMDA receptor blocker ameliorates ischemia-reperfusion-induced renal dysfunction in rat kidneys. Am J Physiol Renal Physiol 2008; 294(6): F1433–1440.
19.Kim EY, Anderson M, Dryer SE. Sustained activation of N-methyl-D-aspartate receptors in podoctyes leads to oxidative stress, mobilization of transient receptor potential canonical 6 channels, nuclear factor of activated T cells activation, and apoptotic cell death. Mol Pharmacol 2012; 82(4): 728–737.
20.Arora S, Kaur T, Kaur A, et al. Glycine aggravates ischemia reperfusion-induced acute kidney injury through N-Methyl-D-Aspartate receptor activation in rats. Mol Cell Biochem 2014; 393(1–2): 123–131.
21.Shen J, Wang R, He Z, et al. NMDA receptors participate in the progression of diabetic kidney disease by decreasing Cdc42-GTP activation in podocytes. J Pathol 2016; 240(2): 149–160.
22.Roshanravan H, Kim EY, Dryer SE. NMDA Receptors as Potential Therapeutic Targets in Diabetic Nephropathy: Increased Renal NMDA Receptor Subunit Expression in Akita Mice and Reduced Nephropathy Following Sustained Treatment with Memantine or MK–801. Diabetes 2016; 65(10): 3139–3150.
23.Kundu S, Pushpakumar S, Sen U. MMP–9- and NMDA receptor-mediated mechanism of diabetic renovascular remodeling and kidney dysfunction: hydrogen sulfide is a key modulator. Nitric Oxide 2015; 46: 172–185.
24.Bozic M, de Rooij J, Parisi E, Ortega MR, Fernandez E, Valdivielso JM. Glutamatergic signaling maintains the epithelial phenotype of proximal tubular cells. J Am Soc Nephrol 2011; 22(6): 1099–1111.
25.Cachat F, Lange-Sperandio B, Chang AY, et al. Ureteral obstruction in neonatal mice elicits segment-specific tubular cell responses leading to nephron loss. Kidney Int 2003; 63(2): 564–575.
26.Francois H, Chatziantoniou C. Renal fibrosis: Recent translational aspects. Matrix Biol 2018; 68–69: 318–332.
27.Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69(2): 213–217.
28.Morikawa M, Derynck R, Miyazono K. TGF-beta and the TGF-beta Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harb Perspect Biol 2016; 8(5).
29.Montesi SB, Desogere P, Fuchs BC, et al. Molecular imaging of fibrosis: recent advances and future directions. J Clin Invest 2019; 129(1): 24–33.
30.Boor P, Sebekova K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007; 22(12): 3391–3407.
31.Nogueira A, Pires MJ, Oliveira PA. Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. In Vivo 2017; 31(1): 1–22.
32.Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75(11): 1145–1152.
33.Adachi T, Sugiyama N, Gondai T, Yagita H, Yokoyama T. Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury. Acta Histochem Cytochem 2013; 46(6): 161–170.
34.Tanaka T. A mechanistic link between renal ischemia and fibrosis. Med Mol Morphol 2017; 50(1): 1–8.
35.Qi R, Yang C. Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury. Cell Death Dis 2018; 9(11): 1126.
36.Xia H, Hornby ZD, Malenka RC. An ER retention signal explains differences in surface expression of NMDA and AMPA receptor subunits. Neuropharmacology 2001; 41(6): 714–723.
37.Zhang W, Chen DQ, Qi F, et al. Inhibition of calcium-calmodulin-dependent kinase II suppresses cardiac fibroblast proliferation and extracellular matrix secretion. J Cardiovasc Pharmacol 2010; 55(1): 96–105.
38.An P, Tian Y, Chen M, et al. Ca(2+) /calmodulin- dependent protein kinase II mediates transforming growth factor-beta-induced hepatic stellate cells proliferation but not in collagen alpha1(I) production. Hepatol Res 2012; 42(8): 806–818.
39.Zhang T, Zhang Y, Cui M, et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med 2016; 22(2): 175–182.
40.Cervantes-Villagrana RD, Adame-Garcia SR, Garcia-Jimenez I, et al. Gbetagamma signaling to the chemotactic effector P-REX1 and mammalian cell migration is directly regulated by Galphaq and Galpha13 proteins. J Biol Chem 2019; 294(2): 531–546.
41.Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68(2): 320–344.
42.Basu RK, Hubchak S, Hayashida T, et al. Interdependence of HIF–1alpha and TGF-beta/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol 2011; 300(4): F898–905.
43.Zhu Y, Gu J, Zhu T, et al. Crosstalk between Smad2/3 and specific isoforms of ERK in TGF-beta1-induced TIMP–3 expression in rat chondrocytes. J Cell Mol Med 2017; 21(9): 1781–1790.
44.Qin J, Mei WJ, Xie YY, et al. Fluorofenidone attenuates oxidative stress and renal fibrosis in obstructive nephropathy via blocking NOX2 (gp91phox) expression and inhibiting ERK/MAPK signaling pathway. Kidney Blood Press Res 2015; 40(1): 89–99.
45.Cheng X, Zheng X, Song Y, et al. Apocynin attenuates renal fibrosis via inhibition of NOXs-ROS-ERK-myofibroblast accumulation in UUO rats. Free Radic Res 2016; 50(8): 840–852.
46.Strippoli R, Loureiro J, Moreno V, et al. Caveolin–1 deficiency induces a MEK-ERK1/2-Snail–1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal dialysis. EMBO Mol Med 2015; 7(1): 102–123.
47.Wu Y, Wang L, Deng D, et al. Renalase Protects against Renal Fibrosis by Inhibiting the Activation of the ERK Signaling Pathways. Int J Mol Sci 2017; 18(5).
48.Jang HS, Han SJ, Kim JI, et al. Activation of ERK accelerates repair of renal tubular epithelial cells, whereas it inhibits progression of fibrosis following ischemia/reperfusion injury. Biochim Biophys Acta 2013; 1832(12): 1998–2008.
49.Pat B, Yang T, Kong C, et al. Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int 2005; 67(3): 931–943.